Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBeacon Pointe Advisors, LLC
Latest Disclosed Ownership17,894 shares
Latest Disclosed Value $ 7,990,485
Beacon Pointe Advisors, LLC reports 32.53% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Beacon Pointe Advisors, LLC filed a 13F-HR form disclosing ownership of 17,894 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $7,990,387 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 18, 2026 disclosing 13,502 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 32.53% during the quarter. The current value of the position is $7,664,716 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,894 4,392 32.53 7,990 30.53 0.0422
2026-02-18 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,502 218 1.64 6,121 17.67 0.0429
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,284 -2,745 -17.13 5,203 -27.10 0.0441
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,029 -196 -1.21 7,136 -9.28 0.0745
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,225 22 0.14 7,866 20.57 0.0883
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,203 -793 -4.67 6,525 -17.46 0.0723
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,996 -2,185 -11.39 7,904 -12.08 0.0911
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,181 -8 -0.04 8,991 12.08 0.1063
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 19,189 -75 -0.39 8,021 2.33 0.0892
2024-02-08 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 19,264 -813 -4.05 7,838 12.28 0.0937
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 20,077 724 3.74 6,982 2.51 0.0870
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,353 -1,753 -8.31 6,811 2.42 0.1112
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,106 -5,230 -19.86 6,650 -12.57 0.1133
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,336 -546 -2.03 7,605 -2.41 0.1475
2022-11-09 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,882 -297 -1.09 7,793 1.68 0.1744
2022-08-11 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 27,179 -753 -2.70 7,664 5.14 0.1618
2022-05-17 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 27,932 5,414 24.04 7,289 47.40 0.0999
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 22,518 -6,314 -21.90 4,945 -5.45 0.1288
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 28,832 17,845 162.42 5,230 136.12 0.1290
2021-08-17 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,987 9,536 657.20 2,215 607.67 0.0785
2021-05-18 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,451 70 5.07 313 -4.28 0.0192
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,381 -183 -11.70 327 -23.24 0.0224
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,564 162 11.55 426 4.41 0.0412
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,402 13 0.94 408 24.01 0.0409
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,389 1,389 329 0.0524
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.